omniture
基石药业(苏州)有限公司 CSTONE PHARMACEUTICALS

Latest News

CStone will present registrational clinical study data of Sugemalimab in patients with stage III non-small cell lung cancer in an oral presentation at ESMO Congress 2021

* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve p...

2021-09-17 08:00 1567

CStone received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody, marking further expansion of its Pipeline 2.0

SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a lead...

2021-09-15 08:30 1221

CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC

* Data with the longer follow-up showed that sugemalimab plus chemotherapy continued to demonstra...

2021-09-14 08:30 1621

CStone Pharmaceuticals Included in the Hong Kong Stock Connect

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "C...

2021-09-06 11:30 2062

CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly impr...

2021-09-02 08:05 1431

CStone Pharmaceuticals Announces 2021 Interim Results

SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading...

2021-08-26 19:14 3448

CStone Pharmaceuticals Selected as a Constituent of HSCI

SUZHOU, China, Aug. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "C...

2021-08-20 20:24 3897

CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021

* AYVAKIT has demonstrated significant anti-tumor activity in Chinese patients with PDGFRA D842V ...

2021-07-08 08:05 1579

CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer

* Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients w...

2021-06-28 08:05 3192

CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully impro...

2021-05-28 08:10 5972
12345